New York physician admits to manslaughter after patient dies of overdose

A New York City physician faces four to nine years in prison after pleading guilty Aug. 13 to second-degree manslaughter for writing prescriptions for a powerful narcotic that led to a patient’s death from overdose, according to a press release from New York Attorney General Letitia James.

Advertisement

As part of his guilty plea, Barry S. Sloan, DO, admitted he issued two prescriptions for fentanyl to a 36-year-old patient in August 2014 without any medical justification. The patient filled the prescriptions four days after they were issued and died the next morning from a fentanyl overdose.

Dr. Sloan also admitted to issuing prescriptions for controlled substances to four other patients without medical justification and providing false information to a Medicaid managed care company.

“Doctors take an oath to heal, not harm people,” Ms. James said in a press release. “With a raging opioid crisis, it is unconscionable that a doctor would recklessly endanger lives by providing fentanyl to healthy patients.”

More articles on legal and regulatory issues:

Patient who woke up covered in bugs at Henry Ford Hospital takes legal action
Washington hospital pays $1.5M to settle age discrimination lawsuit
CHS faces $891M class-action lawsuit

 

 

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Reconsider What’s Possible: Enterprise RCM and the Pro-Fee Practice

Tuesday, July 28
11:00 AM - 12:00 PM CDT

Presenters: Garett Kreitz, Med-MetrixJohn Stefanowicz, Med-MetrixPaul Summers, Nevada Heart & Vascular

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.